Apogee Therapeutics, Inc.

Apogee Therapeutics, Inc. is a clinical stage biotechnology company focused on developing novel biologics for the treatment of inflammatory and immunology indications. Its lead product candidate is Zumilokibart (APG777), a subcutaneous extended half-life monoclonal antibody targeting IL-13, currently in phase 2 clinical trials for atopic dermatitis and in phase 1 for asthma and eosinophilic esophagitis. The company also has APG279 in phase 1 for atopic dermatitis, APG273 in phase 1 for asthma and chronic obstructive pulmonary disease, and APG808, an extended half-life mAb targeting IL-4Ra for Type 2 allergic diseases. Apogee operates in the United States and is headquartered in Waltham, Massachusetts.

Apogee Therapeutics is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol APGE. Its shares are traded in US Dollars (USD), reflecting its primary listing in the United States. The Nasdaq exchange is a major electronic stock market in the US, providing liquidity and visibility for biotechnology companies like Apogee.

Apogee Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. Biotechnology companies use biological processes and living organisms to develop products, often for medical applications. Apogee focuses on developing biologic drugs—large-molecule therapies derived from living cells—to treat inflammatory and immune-mediated diseases such as atopic dermatitis, asthma, and chronic obstructive pulmonary disease.

Apogee Therapeutics is headquartered in Waltham, Massachusetts, United States. The company primarily serves the US market, as indicated by its description focusing on the United States for its clinical trials and operations. Its pipeline targets diseases prevalent in the US, such as atopic dermatitis and asthma, and it conducts clinical trials domestically. While the company may eventually expand globally, its current focus is on the US healthcare market.

Apogee Therapeutics is a clinical-stage biotechnology company that generates value by developing novel biologic therapies for inflammatory and immunology indications. It does not yet have approved products or revenue from sales; instead, its business model relies on advancing its pipeline through clinical trials to eventually seek regulatory approval and commercialization. Key pipeline products include Zumilokibart (APG777) for atopic dermatitis, asthma, and eosinophilic esophagitis; APG279 for atopic dermatitis; APG273 for asthma and COPD; and APG808 for Type 2 allergic diseases. These biologics are designed with extended half-lives to allow less frequent dosing, potentially offering competitive advantages.